Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01280994 · ClinicalTrials.gov registry record · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
A Phase 2 study of Interstitial Lung Disease, sponsored by Bastiaan Driehuys.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 445
- Enrollment target
- 1
- Study location
NCT01280994: Recruiting Phase 2 study of Interstitial Lung Disease, sponsored by Bastiaan Driehuys.
NCT01280994 is a Phase 2 study of Interstitial Lung Disease that is actively recruiting participants, run by Bastiaan Driehuys. The registered enrollment target is 445 participants, below the 554-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01280994, a Phase 2 study of Interstitial Lung Disease, is actively recruiting participants, sponsored by Bastiaan Driehuys.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 445 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar microstructure via the 129Xe apparent diffusion coefficient (ADC), and 3) imaging 129Xe that dissolves in the pulmonary blood and tissues upon inhalation. Such imaging of 129Xe gas transfer is expected to be uniquely sensitive to pathologies affecting gas exchange (fibrosis, emphysema, pulmonary hypertension) and provide new insights regarding the normal resting heterogeneity of pulmonary gas exchange.
Primary Outcome
The purpose of this trial is to examine the ability of HP 129Xe imaging to characterize the lung in healthy and diseased states. The safety endpoint for each subject is to record any adverse events as a measure of safety and tolerability. The technical endpoint for each subject is the acquisition of technically adequate HP 129Xe MR images.
Conditions Studied
Interventions
- DRUG Hyperpolarized 129Xenon Gas
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2011-01 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
What NCT01280994 shows while recruiting
NCT01280994 is an interventional study that assigns participants to a tested intervention. The registered 445 participants enrollment target is mid-sized for trials with a published cap, below the 554-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Interstitial Lung Disease appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 129Xenon Gas is the first listed.
NCT01280994 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01280994 about?
NCT01280994 is a clinical study titled "Hyperpolarized 129Xe MRI for Imaging Pulmonary Function". The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar micros...
What is the current status of trial NCT01280994?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 445 participants. The study started on 2011-01. Estimated completion is 2030-12.
What conditions does trial NCT01280994 study?
This clinical trial studies the following conditions: Interstitial Lung Disease.
What interventions are being tested in trial NCT01280994?
The interventions under investigation include: Hyperpolarized 129Xenon Gas (DRUG).
Who is sponsoring clinical trial NCT01280994?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01280994 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01280994's enrollment target sits among peer trials
445 10th of 36 higher than 27 of 36 other Interstitial Lung Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Interstitial Lung Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
- NCT04751435 · 445 participants · NA
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia